SynthesisFrontiers in immunology2026
Efficacy and safety of cadonilimab combined with chemotherapy for gastric or gastroesophageal junction adenocarcinoma: a single-arm meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bispecific antibodies in gastrointestinal cancers: current applications and future perspectives.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) combined with chemotherapy have become an important area of clinical investigation in the gastric cancer (GC) and gastroesophageal junction cancer (GEJC). In recent years, bispecific antibody therapies have been increasingly explored, including cadonilimab, a programmed death-1/cytotoxic T-lymphocyte-associated antigen 4 (PD-1/CTLA-4) bispecific antibody. Several phase II studies have reported early signals of antitumor activity with cadonilimab, prompting clinical interest in this strategy. However, treatment outcomes vary across studies, and a systematic assessment of the efficacy and safety of cadonilimab plus chemotherapy remains limited. This study aimed to evaluate the efficacy and safety profile of cadonilimab in combination with chemotherapy for gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (G/GEJ adenocarcinoma) through a single-arm meta-analysis. Methods: A systematic search was conducted in PubMed, Embase, the Cochrane Library, Web of Science, and ClinicalTrials.gov to identify eligible studies published up to July 20, 2025. A single-arm meta-analysis was performed to pool and evaluate the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), pathological complete response (pCR), and the incidence of grade ≥3 treatment-related adverse events (TRAEs). Results: A total of four clinical studies involving 182 patients were included. The pooled estimates were an ORR of 57% (95% CI: 48%-66%), a DCR of 97% (95% CI: 84%-100%), a pCR of 23% (95% CI: 12%-35%), and a median PFS of 7.98 months (95% CI: 6.38-9.57). The overall incidence of grade ≥3 TRAEs was 35% (95% CI: 7%-63%). In subgroup analyses, the incidence of grade ≥3 TRAEs appeared lower in the neoadjuvant setting than in the first-line setting (29% [95% CI: 28%-40%] vs 53% [95% CI: 45%-60%]). The most frequently reported adverse events included nausea (72%), vomiting (60%), neutropenia (51%), and leukopenia (45%). Conclusions: Based on available early-phase evidence, cadonilimab plus chemotherapy showed antitumor activity with a manageable safety profile in G/GEJ adenocarcinoma. Further large-scale, high-quality randomized controlled trials are needed to validate these findings and define the optimal treatment strategy. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO, identifier CRD420251089855.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.